The death took place recently in Chicago, USA of Julie Corduff. The deceased was the daughter of Kate and Peter Sheridan RIP, ...

AbbVie's growth thrives on strong earnings, a robust immunology portfolio, and diversification. See why ABBV stock is a ...

Johnson & Johnson may outshine AbbVie as a top defensive stock pick. Read how Ben Graham's framework evaluates each ...

In 2024, combined Skyrizi and Rinvoq sales reached $17.7 billion, up 51% year over year, reflecting accelerating global ...

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...

AbbVie Inc. closed 5.34% below its 52-week high of $207.32, which the company reached on October 31st.

Large American pharmaceutical companies are showing a distinct trend never seen before: they are increasingly looking for ...

AbbVie is using innovative technologies like AI, wearables and automation to speed up drug discovery, clinical trials, and ...

AbbVie (NYSE: ABBV) closed out a pivotal 2024 ... This level is particularly compelling, given its expected earnings momentum and the number of potential catalysts from the research and ...

AbbVie CEO Robert Michael will soon add the role of board chairman to his résumé. Michael, who became CEO of the North Chicago-based pharmaceutical giant last summer, will assume duties as ...